Biosearch

Biosearch Equity

Delisted

The The Equity of Biosearch (BIO.MC) as of Sep 16, 2026 is 25.17 M EUR. In the previous year, The Equity was 23.74 M EUR — a change of 6.04% (higher).

Equity

25.17 MEUR

YoY

6.04%

Last updated:

In 2026, Biosearch's equity was 25.17 M EUR, a 6.04% increase from the 23.74 M EUR equity in the previous year.

The Biosearch Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2014
22.70 M EUR
Jan 1, 2015
22.39 M EUR
Jan 1, 2016
18.80 M EUR
Jan 1, 2017
20.65 M EUR
Jan 1, 2018
23.12 M EUR
Jan 1, 2019
23.74 M EUR
Jan 1, 2020
25.17 M EUR
The Biosearch Equity history
YEAREquityYoY
25.17 MEUR+6.04%
23.74 MEUR+2.69%
23.12 MEUR+11.92%
20.65 MEUR+9.84%
18.80 MEUR-16.02%
22.39 MEUR-1.35%
22.70 MEUR—
Access this data via the Eulerpool API
Get Free API Key

Biosearch Stock analysis

What does Biosearch do? Biosearch SA is a Spanish company specializing in the development, production, and distribution of nutrients for the healthcare industry. The company was founded in 1993 and is headquartered in Granada, Spain. Since then, it has played a significant role in the industry and is now considered one of the leading providers of products for the healthcare sector. Biosearch is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Biosearch's Equity

Biosearch's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Biosearch's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Biosearch's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Biosearch's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Biosearch’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Biosearch stock

The Equity of Biosearch is 25.17 M EUR in 2026.

The Equity of Biosearch changed from 23.74 M EUR to 25.17 M EUR, representing a 6.04% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Biosearch since 2006 – with annual values, charts, and detailed analysis.

The Equity's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Biosearch historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Biosearch

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Biosearch